Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 2Neurotoxicity Syndromes 1Hematologic Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 3Amifostine 3Vincristine 2Procarbazine 2haloperidol decanoate 1axicabtagene ciloleucel 1Thalidomide 1Tadalafil 1Surveys and Questionnaires 1SLI381 1Rituximab 1Radiotherapy 1Prednisolone 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 1Modafinil 1Methylphenidate 1Methotrexate 1Melphalan 1Lorazepam 1Leucovorin 1Interleukin 1 Receptor Antagonist Protein 1In Situ Hybridization, Fluorescence 1Glutamine 1Gene Expression Profiling 1Folfox protocol 1Fluorouracil 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neurotoxicity Syndromes × Duloxetine Hydrochloride × Clear all
NCT06551051 2024-09-19

ADC-induced Neurotoxicity Treated With Duloxetine

Fudan University

Phase 2 Recruiting
37 enrolled

Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡